301188 Shandong Linuo Technical Glass
- 18.75
- +0.17+0.91%
Shandong Linuo Technical Glass News
Linuo Tebo (301188): Q1 gross margin improved year-on-year, expecting a breakthrough in new products
The incident described achieving revenue of 947 million yuan in 2023, up 15.25% year on year; attributable net profit of 66 million yuan, down 43.49% year on year; equivalent to Q4 revenue of 256 million yuan, up 1.29% year on year; ownership
Linuo Tebo (301188): Revenue growth is steady, and the volume of borosilicate molded bottles is about to be released
Incident: The company disclosed its 2024 quarterly report, achieving operating income of 267 million yuan, an increase of 18.99%; net profit to mother of 24.8.063 million yuan, an increase of 8.22% over the previous year; after deducting non-net profit of 2213.34
Express News | Linuote Glass Borosilicate Glass Molded Injection Bottle Registration Number Transfer to “A”
Linuo Tebo (301188): Evaluation of formulations related to borosilicate molded injection bottles approved
Incident: The company's borosilicate glass molded injection bottle recently passed the technical review by the Drug Evaluation Center (CDE) of the State Drug Administration, and the registration number was changed to the CDE registration information disclosure platform for active ingredients, pharmaceutical excipients and pharmaceutical packaging materials
A-share midday announcement: Grimmie signs strategic cooperation agreement to jointly promote large-scale equipment upgrades and consumer goods trade-in
① Grimmie: The company and 21 partners including Shenzhen SF Integrated Logistics Service Co., Ltd., Guangzhou Shiyuan Electronic Technology Co., Ltd., Jingjin Equipment Co., Ltd., Suzhou Huichuan Technology Co., Ltd., Fangzheng Valve Group Co., Ltd., Shandong Tianli Energy Co., Ltd., Weiming Environmental Protection Equipment Group Co., Ltd., Emerson Process Control Co., Ltd. signed a strategic cooperation agreement on April 30 to jointly build a digital recycling platform, establish a reverse recycling logistics supply chain service system, and carry out equipment upgrade and remanufacturing. Next display and supply chain sales are big
Linuo Tebo (301188.SZ): The results of the joint review and approval of the company's borosilicate glass molded injection bottles and formulations changed to A status
Gelonghui, April 30 | Linuotebo (301188.SZ) announced that the company's borosilicate glass molded injection bottle recently passed the technical review by the Drug Evaluation Center of the State Drug Administration (hereinafter referred to as “CDE”), and the registration number has changed to “A” status on the CDE API, pharmaceutical excipients and pharmaceutical packaging materials registration information disclosure platform. The company's borosilicate glass molded injection bottles indicate that the borosilicate glass molded injection bottles produced by the company can be officially sold in batches after the relevant formulations are approved (converted to “A” status). This time, the company's borosilicate glass molded injection bottle changed to an “A” shape
Linuo Tebo (301188) Company Incident Review Report: China Borosilicate Molded Bottle Turns A to Landing Performance Growth Can Be Expected
Borosilicate molded bottles are converted to A, and performance increases can be expected. Incident: Linotebo borosilicate glass molded injection bottles recently passed the technical review by the Drug Evaluation Center of the State Drug Administration, and have been listed in CDE as raw materials, pharmaceutical excipients and pharmaceutical packaging materials
Linuo Tebo (301188) Company's 2023 Report and 2024 Quarterly Report Review Report: Rising Costs Are Pressuring Performance and Accelerating the Layout of Borosilicate Pharmaceutical Glass
Revenue from heat-resistant glass recovered under pressure due to rising costs. China Borosilicate Pharmaceutical Glass Accelerated Layout released the 2023 Annual Report and the 2024 First Quarter Report. In 2023, it achieved revenue of 947 million yuan, +15.25% over the same period last year, and returned to the mother
Express News | Linotebo: Net profit fell 43.5% year on year in 2023
Linuo Tebo (301188.SZ): The borosilicate medicinal glass tube project has been produced according to the design plan
Gelonghui, April 12 | Linuotebo (301188.SZ) said on the investor interactive platform that the borosilicate medicinal glass tube project has been produced according to the design plan. The pass rate meets the design requirements, and can produce about 5,000 tons of products per year, mainly for the company's own use in the production of borosilicate control bottles.
Linuo Tebo (301188.SZ): The controlling shareholder transferred a total of 700,000 “Linuo Convertible Bonds”
Glonghui on March 6 | Linuo Tebo (301188.SZ) announced that on March 6, 2024, the company received a notice from Linuo Investment, the controlling shareholder, and learned that between March 1, 2024 and March 5, 2024, it transferred a total of 700,000 “Linuo Convertible Bonds” in bulk transactions through the Shenzhen Stock Exchange System, accounting for 14.00% of the total amount issued. After this change, Linuo Investment, the controlling shareholder of the company, held 856,151 “Linuo Convertible Bonds”, accounting for 17.12% of the total issuance volume.
Linuo Tebo (301188.SZ): 1.40% of shares have been repurchased cumulatively
Glonghui, March 4 | Linuottebo (301188.SZ) announced that as of February 29, 2024, the company used its own funds to repurchase a total of 3,255,000 shares through a dedicated securities account, accounting for 1.40% of the company's current total share capital. The highest transaction price for the repurchased shares was 16.00 yuan/share, and the minimum transaction price was 12.339 yuan/share. The total transaction amount was 45,642,890.54 yuan (excluding transaction fees).
Linuo Tebo (301188.SZ): Currently, the company's borosilicate molded bottles are in the normal related approval stage
Gelonghui, Feb. 19: An investor asked Linuotebo (301188.SZ) on the investor interactive platform, “Shandong Dingxin Pharmaceutical Packaging Group applied for transfer to A, and the company hasn't transferred A yet, is the company's product not working?” The company replied that currently the company's borosilicate molded bottle is in the normal related approval stage and is progressing in an orderly manner according to the plan. Follow-up progress The company will promptly fulfill its disclosure obligations in accordance with relevant laws and regulations. Please stay tuned for the company's subsequent relevant announcements.
Linuo Tebo (301188): China borosilicate medicine glass faucet accelerates growth and a breakthrough in molded bottle expansion is imminent
Leading specialty glass enterprises, pharmaceutical glass upgrades and growth are accelerating. The company was founded in 2002 and began production of high borosilicate heat-resistant glass and low borosilicate pharmaceutical glass. In 2017-2022, the company's operating income and net profit to mother started at 5.0/
Linuo Tebo (301188.SZ): Initial repurchase of 196,000 shares involving 3.107.75 million yuan
Glonghui, January 31, 丨 Linuo Tebo (301188.SZ) announced that on January 30, 2024, the company first implemented a share repurchase through a special securities account for share repurchases. The number of shares repurchased was 196,000 shares, accounting for 0.08% of the company's current total share capital. The highest transaction price was 16.00 yuan/share, the minimum transaction price was 15.70 yuan/share, and the total transaction amount was 310.77.51 million yuan (excluding transaction fees).
Linuo Tebo (301188): The fundamental inflection point is expected to arrive, and the production capacity volume of molded bottles can be expected
Demand for terminals continues to recover, and the pharmaceutical glass business is growing beautifully. The company's 23Q1-3 revenue was 691 million yuan, up 21.5%. The company's revenue in '22 was 822 million, a decrease of 7.5%, mainly due to the decline in revenue from the heat-resistant glass business.
Linuotebo (301188.SZ) plans to acquire a 51% stake in the Egyptian pharmaceutical packaging glass manufacturer EAC
Linotebo (301188.SZ) Announcements, Inc., and The European Ampo of Egypt...
Express News | Linuo Tebo: The company plans to acquire 51% of EAC's shares in the form of a combination of equity transfer and capital increase
Linuo Tebo (301188.SZ): Proposed to establish wholly-owned subsidiaries Shandong Linuo Glass Technology and Shandong Linuo Optoelectronics Technology
Gelonghui, January 16, 丨 Linuo Tebo (301188.SZ) announced that the company held the 24th meeting of the 3rd board of directors on January 16, 2024 to review and pass the “Proposal on Investment and Establishment of Wholly-owned Subsidiaries”, agreeing that the company will invest its own capital to establish two wholly-owned subsidiaries Shandong Linuo Glass Technology Co., Ltd., Shandong Linuo Optoelectronics Technology Co., Ltd. (tentative name, subject to final registration approval by the administrative department for industry and commerce). The proposed registered capital is RMB 10 million. At the same time, the company management is authorized to apply for the industrial and commercial registration of the target company in accordance with the provisions of laws and regulations
Linuo Tebo (301188.SZ): Plans to spend 50 million yuan to 60 million yuan to buy back the company's shares
On January 16, Gelonghui (301188.SZ) announced an announcement on the plan to repurchase the company's shares. The total capital for the repurchase of shares is not less than RMB 50 million (inclusive) and not more than RMB 60 million (inclusive). The repurchase price does not exceed RMB 22 per share (including the number of shares). All of the shares repurchased will be used for equity incentive plans or employee stock ownership plans. According to the minimum repurchase amount and maximum repurchase price estimates, the estimated number of shares that can be repurchased is about 2.2727.27 million shares, accounting for 0.98% of the company's total share capital; calculated based on the maximum repurchase amount and maximum repurchase price
Analysis
Price Target
No Data
